Immatics
NEWS
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
Leading immuno-oncology company adopts Genedata Biologics® to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules
The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
JOBS
IN THE PRESS